Danaher Corporation Stock Price, News & Analysis

Danaher (NYSE: DHR) has reaffirmed its previously issued guidance for the third quarter and full year 2024. The company expects non-GAAP core revenue to decline by low-single digits year-over-year for both periods. This confirmation comes ahead of a scheduled analyst event on September 5, 2024, in Washington, D.C., hosted by Julie Sawyer Montgomery, Executive Vice President of Diagnostics.

Danaher provides forecasts only on a non-GAAP core revenue basis due to difficulties in estimating other GAAP revenue components such as currency translation, acquisitions, and divested product lines. The analyst meeting will be webcast on Danaher's website, with a replay available after the presentation.

Danaher (NYSE: DHR) has announced a live video webcast of its Diagnostics Investor and Analyst Meeting scheduled for September 5, 2024 in Washington, D.C. The event will start at approximately 10:00 a.m. ET and will be hosted by Julie Sawyer Montgomery, Executive Vice President of Diagnostics.

Investors and analysts can access the webcast and accompanying slide presentation through the 'Investors' section of Danaher's website, www.danaher.com, under the 'Events & Presentations' subheading. For those unable to attend the live event, a replay of the video webcast will be made available following the presentation.

Beckman Coulter Diagnostics announced that its DxI 9000 Immunoassay Analyzer was honored at Premier, Inc.'s annual supplier Innovation Celebration. The analyzer boasts the highest throughput in the market and delivers the highest percentage of Six Sigma assays. A key feature is the Lumi-Phos PRO substrate, enabling measurement of analytes at the attomole level, equivalent to detecting a teaspoon of sugar in 100,000 Olympic-sized pools. This analytical sensitivity opens new possibilities for complementary diagnostics and revised claims for established assays. The recognition highlights Beckman Coulter's commitment to advancing healthcare through innovative solutions that enhance patient care, streamline operations, and improve efficiency.

Danaher (NYSE: DHR) reported its Q2 2024 results, with net earnings of $907 million or $1.22 per diluted share. Non-GAAP adjusted diluted EPS was $1.72. Revenues decreased 3.0% year-over-year to $5.7 billion, while non-GAAP core revenue decreased 3.5%. Operating cash flow was $1.4 billion, and non-GAAP free cash flow was $1.1 billion.

CEO Rainer M. Blair noted better-than-expected revenue, earnings, and cash flow, highlighting sustained momentum in bioprocessing and strong performance at Cepheid. For Q3 2024, Danaher anticipates non-GAAP core revenue to be down low-single digits year-over-year. The full-year 2024 outlook remains unchanged, expecting non-GAAP core revenue to be down low-single digits year-over-year.

Danaher (NYSE: DHR) has announced the launch of two new Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified labs aimed at accelerating the development of Companion Diagnostics (CDx) and Complementary Diagnostics (CoDx). These centers of innovation are designed to streamline the development and commercialization of precision medicine.

The first lab, opening in Newcastle, UK in July, will serve as a hub for collaborative research with pharmaceutical and academic institutions. A second center in the United States is scheduled to open later this year, featuring capabilities such as immunohistochemistry, PCR, and immunoassay. These labs aim to minimize hand-offs in the diagnostic development process, potentially reducing the time from discovery to FDA approval for CDx and CoDx tests.

Danaher (NYSE: DHR) has released its 2024 Sustainability Report, highlighting key achievements across its strategic pillars. The company has made significant progress in innovating products, building diverse teams, and protecting the environment.

Notable accomplishments include:

• Updating product development tools to consider customer sustainability needs
• Increasing female representation to 40% and U.S. People of Color representation to 42%
• Maintaining pay equity for women globally and racial/ethnic minorities in the U.S.
• Committing to science-based GHG emission reduction targets, including a net-zero goal by 2050
• Launching an enterprise-wide climate risk assessment based on TCFD recommendations
• Assessing sustainability practices of suppliers representing 75% of annual spend

Danaher's commitment to continuous improvement drives its efforts to make a positive impact on the world through innovation, teamwork, and environmental protection.

On July 11, 2024, Danaher (NYSE: DHR) announced a research collaboration with Stanford University's Department of Bioengineering. The initiative, part of the Danaher Beacon for Spatialomics, aims to develop advanced 'smart microscopy' tools for cancer drug screening. This technology combines spatial biology with artificial intelligence (AI) to better analyze tumor heterogeneity, a critical factor in the high failure rates of oncology drug trials. The collaboration involves Leica Microsystems, a Danaher subsidiary, and Dr. Emma Lundberg of Stanford. The goal is to create AI-driven phenotyping technology that can vastly improve the accuracy of drug screening and lead to more effective cancer treatments.

Beckman Coulter Diagnostics has introduced the DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay system. Tailored for satellite and independent labs, the DxC 500i offers flexibility, scalability, and data commutability with a comprehensive assay menu. The system combines DxC 500 AU Chemistry Analyzer technology with Six Sigma performance, facilitating efficient, high-quality results. It prioritizes immunoassay and chemistry testing based on sample urgency and features a dynamic sample handler. The intuitive interface supports new users with proactive task indicators and step-by-step instructions. Currently available in CE-mark-accepting countries, the analyzer awaits FDA clearance for U.S. markets.

Danaher has scheduled its Q2 2024 earnings conference call for July 23, 2024, at 8:00 a.m. ET. The webcast will include discussions on financial performance and future expectations, accompanied by a slide presentation. The call, hosted on Danaher's website, will be available for replay until the next earnings call. Dial-in numbers for the call are 800-245-3047 (U.S.) and +1 203-518-9765 (international) with Conference ID: DHRQ224. Earnings materials will be posted on the website on the day of the call at 6:00 a.m. ET.